Planta Med 2022; 88(15): 1561
DOI: 10.1055/s-0042-1759315
Poster Session II

Phytotherapy for pain: data from the PhytoVIS study, a NIS in 20,870 users of herbal medicinal products

N Mischer
1   Phytomedicines Supply and Development Center, R&D, Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
,
O Kelber∗
1   Phytomedicines Supply and Development Center, R&D, Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
2   Kooperation Phytopharmaka GbR, Bonn, Germany
,
E Raskopf
3   Institute for Medical Statistics and Bioinformatics, University Clinics Cologne, Cologne, Germany
4   ClinCompetence, Cologne, Germany
,
I Frohne
5   Policlinic, functional area & Hiller Research Center for Rheumatology, University Clinics Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
,
J G Richter
5   Policlinic, functional area & Hiller Research Center for Rheumatology, University Clinics Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
,
K Nieber
6   Institute of Pharmacy, University of Leipzig, Leipzig, Germany
2   Kooperation Phytopharmaka GbR, Bonn, Germany
› Author Affiliations
› Further Information
Also available ateRef
 

Introduction: Herbal medicinal products (HMPs) are widely used by patients suffering from pain. However, clinical studies are only available for some of the products, meaning that pharmacoepidemiological data can be an important source of information.

Aims: Therefore, data from the PhytoVIS study, probably the worldʼs largest pharmacoepidemiological study on the use of HMPs [1], were evaluated.

Methods: The PhytoVIS data were collected in medical practices and pharmacies in accordance with the specifications of the ENCePP code [2] and screened based on indication groups.

Results: A total of 1,350 of a total of 24,056 datasets document the use of HPMs for pain treatment. Patients of all ages used HMPs. Formulations for external use dominated with 30% to 50%, especially in children and elderly patients, followed by solid and liquid oral dosage forms. CGI-E self-reported effect assessment was best for e.g. neck pain, bruises, back pain and headaches, and still good for e.g., migraine and arthralgia. More than 90% of the patients in each age group rated the tolerability as “good” and no intolerances of concern were reported. About 25% of HMPs were recommended by pharmacists and 15% by medical doctors.

Discussion and conclusions: As the patients reported, the phytotherapy for pain was well tolerated and effective. The data be utilized as a basis for therapy decisions.

Acknowledgments

The study was supported by Kooperation Phytopharmaka GbR, Bonn, Germany


 


Publication History

Article published online:
12 December 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Raskopf E, Greinert O, Zadoyan G. et al. Die Versorgungsforschungs-Datenbank PhytoVIS – eine retrospektive Befragung zur Anwendungserfahrung mit Phytopharmaka. Z Phytother 2017; 38(S01): S1-44
    PubMedSearch in Google Scholar
  • 2 European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP), 2018, EMA/929209/2011.
    PubMed